產品詳情
簡單介紹：
HB-10744 SH-3 鼠雜交瘤細胞，ATCC 細胞|細胞系|細胞株|腫瘤細胞株|細胞|貼壁細胞|懸浮細胞|；細胞庫管理規范，提供的細胞株背景清楚，提供參考文獻和Z優培養條件
詳情介紹：
HB-10744 SH-3 鼠雜交瘤細胞
ATCC® Number: HB-10744? Price: $399.00
Designations: SH3
Depositors: Osiris Therapeutics, Inc.
Isotype: IgG2b
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human mesenchymal stem cells
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: Animals were immunized with human mesenchymal stem cells.
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin.
Propagation: ATCC complete growth medium: Modified Dulbecco's medium, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: recommended serum:ATCC 30-2020
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 46-X
References: 22086: Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996
49752: Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137
| ATCC® Number: | HB-10744? | Price: | $399.00 | |||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Designations: SH3
Depositors: Osiris Therapeutics, Inc.
Isotype: IgG2b
Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: suspension
Organism: Mus musculus (B cell); Mus musculus (myeloma) (mouse (B cell); mouse (myeloma))
Morphology: lymphoblast
Source: Cell Type: hybridoma: B lymphocyte;
Cellular Products: immunoglobulin; monoclonal antibody; against human mesenchymal stem cells
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Tumorigenic: Yes
Comments: Animals were immunized with human mesenchymal stem cells.
Spleen cells were fused with Sp2/0-Ag14 mouse myeloma cells.
The antibody reacts with mesenchymal stem cells from bone marrow and some tissues of mesenchymal origin.
Propagation: ATCC complete growth medium: Modified Dulbecco's medium, 85%; fetal bovine serum, 15%
Temperature: 37.0°C
Subculturing: Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 2 X 10 exp5 and 1 X 10 exp6 cells/ml.
Preservation: culture medium 95%; DMSO, 5%
Related Products: recommended serum:ATCC 30-2020
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 46-X
References: 22086: Caplan AI, Haynesworth SE. Human mesenchymal stem cells. US Patent 5,486,359 dated Jan 23 1996
49752: Haynesworth SE, et al. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 13: 69-80, 1992. PubMed: 1316137
